Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Mr. Thomas H. Glanzmann

Executive Chairman

Mr. Alfredo Arroyo Guerra

Chief Financial Officer & Vice President

Ms. Nuria Pascual Lapeña

Vice President of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer

Ms. Maria  Teresa-Rioné Llano

Chief Communications Officer

Mr. Sergio Roura Adell

President of Commercial Tech Support

Mr. Camille  Alpi

Chief Human Resources & Talent Officer

Mr. Vicente  Blanquer Torre

Chief Quality Officer

Mr. Jose Ignacio  Abia Buenache

Chief Executive Officer & Director

Mr. Lluis Pons Gomez

Senior Vice President of Strategy & Chief Operating Officer Office

Mr. David Ian Bell

Chief Corporate Development, Legal & Data Protection Officer

Pavadinimas	Rinkos kapitalizacija
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Bristol-Myers Squibb Company	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M

Grifols, S.A.

Grifols, S.A. Konkurentų sąrašas

Pagrindiniai konkurentai